logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
Y

Yung-Jue Bang

seoul national university (snu)
H指数:106
被引数:6.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

曲妥珠单抗deruxtecan治疗HER2-positive晚期胃癌: 随机2期DESTINY-Gastric01试验的探索性生物标志物分析

NATURE MEDICINE
IF50
2024-05-142
OAAI
Shitara, Kohei; Bang, Yung-Jue; Iwasa, Satoru; Sugimoto, Naotoshi; Ryu, Min-Hee; Sakai, Daisuke; Chung, Hyun Cheol; Kawakami, Hisato; Yabusaki, Hiroshi; Sakamoto, Yasuhiro; Nishina, Tomohiro; Inaki, Koichiro; Kuwahara, Yusuke; Wada, Naoya; Suto, Fumitaka; Arita, Takeo; Sugihara, Masahiro; Tsuchihashi, Zenta; Saito, Kaku; Kojima, Akihito; Yamaguchi, Kensei
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

Zolbetuximab联合CAPOX治疗CLDN18.2阳性胃或胃食管交界处腺癌: 随机，3期GLOW试验

NATURE MEDICINE
IF50
2023-07-31158
OAAI
Shah, Manish A.; Shitara, Kohei; Ajani, Jaffer A.; Bang, Yung-Jue; Enzinger, Peter; Ilson, David; Lordick, Florian; Van Cutsem, Eric; Plazas, Javier Gallego; Huang, Jing; Shen, Lin; Oh, Sang Cheul; Sunpaweravong, Patrapim; Soo Hoo, Hwoei Fen; Turk, Haci Mehmet; Oh, Mok; Park, Jung Wook; Moran, Diarmuid; Bhattacharya, Pranob; Arozullah, Ahsan; Xu, Rui-Hua
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro- oesophageal junction adenocarcinoma (SPOTLIGHT) : a multicentre, randomised, double-blind, phase 3 trial

Zolbetuximab联合mFOLFOX6治疗CLDN18.2阳性，HER2-negative，未治疗，局部晚期不可切除或转移性胃或胃食管交界处腺癌 (SPOTLIGHT): 一项多中心，随机，双盲，3期试验

LANCET
IF88.5
2023-05-01246
PRE
Shitara, Kohei; Lordick, Florian; Bang, Yung-Jue; Enzinger, Peter; Ilson, David; Shah, Manish A.; Van Cutsem, Eric; Xu, Rui-Hua; Aprile, Giuseppe; Xu, Jianming; Chao, Joseph; Pazo-Cid, Roberto; Kang, Yoon-Koo; Yang, Jianning; Moran, Diarmuid; Bhattacharya, Pranob; Arozullah, Ahsan; Park, Jung Wook; Oh, Mok; Ajani, Jaffer A.
Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study
CANCER RESEARCH
IF16.6
2023-04-140
PRE
Subbiah, Vivek; Kreitman, Robert J.; Wainberg, Zev A.; Gazzah, Anas; Lassen, Ulrik; Stein, Alexander; Wen, Patrick Y.; Dietrich, Sascha; Jonge, Maja J. A.; Blay, Jean-Yves; Italiano, Antoine; Yonemori, Kan; Cho, Daniel C.; de Vos, Filip Y. F. L.; Moreau, Philippe; Fernandez, Elena Elez; Schellens, Jan H.; Zielinski, Christoph C.; Redhu, Suman; Passos, Vanessa Q.; Ilankumaran, Palanichamy; Bang, Yung-Jue
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
NATURE MEDICINE
IF50
2023-04-1495
OAAI
Subbiah, Vivek; Kreitman, Robert J.; Wainberg, Zev A.; Gazzah, Anas; Lassen, Ulrik; Stein, Alexander; Wen, Patrick Y.; Dietrich, Sascha; de Jonge, Maja J. A.; Blay, Jean-Yves; Italiano, Antoine; Yonemori, Kan; Cho, Daniel C.; de Vos, Filip Y. F. L.; Moreau, Philippe; Fernandez, Elena Elez; Schellens, Jan H. M.; Zielinski, Christoph C.; Redhu, Suman; Boran, Aislyn; Passos, Vanessa Q.; Ilankumaran, Palanichamy; Bang, Yung-Jue
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)

INTEGRATE II: 包含regorafenib的方案与难治性晚期胃食道癌 (AGOC) 的护理标准的随机III期对照试验: 澳大利亚胃肠道试验组 (AGITG) 的一项研究

BMC CANCER
IF3.4
2023-02-227
OAAI
Lam, Lyn Ley; Pavlakis, Nick; Shitara, Kohei; Sjoquist, Katrin M.; Martin, Andrew J.; Yip, Sonia; Kang, Yoon-Koo; Bang, Yung-Jue; Chen, Li-Tzong; Moehler, Markus; Bekaii-Saab, Tanios; Alcindor, Thierry; O'Callaghan, Christopher J.; Tebbutt, Niall C.; Hague, Wendy; Chan, Howard; Rha, Sun Young; Lee, Keun-Wook; Gebski, Val; Jaworski, Anthony; Zalcberg, John; Price, Timothy; Simes, John; Goldstein, David
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
CLINICAL CANCER RESEARCH
IF10.2
2022-06-1314
OAAI
Kim, Tae Won; Burris, Howard A.; Luken, Maria J. de Miguel; Pishvaian, Michael J.; Bang, Yung-Jue; Gordon, Michael; Awada, Ahmad; Camidge, D. Ross; Hodi, F. Stephen; McArthur, Grant A.; Miller, Wilson H., Jr.; Cervantes, Andres; Chow, Laura Q.; Lesokhin, Alexander M.; Rutten, Annemie; Sznol, Mario; Rishipathak, Deepali; Chen, Shang-Chiung; Stefanich, Eric; Pourmohamad, Tony; Anderson, Maria; Kim, Jeong; Huseni, Mahrukh; Rhee, Ina; Siu, Lillian L.
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab plus Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study

在KEYNOTE-062 III期研究中，肿瘤突变负荷与Pembrolizumab加化疗作为胃癌一线治疗的疗效之间的关系

CLINICAL CANCER RESEARCH
IF10.2
2022-06-038
OA
Lee, Keun-Wook; Van Cutsem, Eric; Bang, Yung-Jue; Fuchs, Charles S.; Kudaba, Iveta; Garrido, Marcelo; Chung, Hyun Cheol; Lee, Jeeyun; Castro, Hugo R.; Chao, Joseph; Wainberg, Zev A.; Cao, Z. Alexander; Aurora-Garg, Deepti; Kobie, Julie; Cristescu, Razvan; Bhagia, Pooja; Shah, Sukrut; Tabernero, Josep; Shitara, Kohei; Wyrwicz, Lucjan
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

紫杉醇 ± Napabucasin在预处理的晚期胃或胃食管交界处腺癌中的随机，双盲，安慰剂对照III期研究

CLINICAL CANCER RESEARCH
IF10.2
2022-05-313
OAAI
Shah, Manish A.; Shitara, Kohei; Lordick, Florian; Bang, Yung-Jue; Tebbutt, Niall C.; Metges, Jean-Phillippe; Muro, Kei; Lee, Keun-Wook; Shen, Lin; Tjulandin, Sergei; Hays, John L.; Starling, Naureen; Xu, Rui-Hua; Sturtz, Keren; Fontaine, Marilyn; Oh, Cindy; Brooks, Emily M.; Xu, Bo; Li, Wei; Li, Chiang J.; Borodyansky, Laura; Van Cutsem, Eric
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

Pembrolizumab与紫杉醇治疗先前治疗的PD-L1-positive晚期胃癌或胃食管交界癌: 随机3期KEYNOTE-061试验的2年更新

GASTRIC CANCER
IF5.1
2021-09-01100
OAAI
Fuchs, Charles S.; Ozguroglu, Mustafa; Bang, Yung-Jue; Di Bartolomeo, Maria; Mandala, Mario; Ryu, Min-Hee; Fornaro, Lorenzo; Olesinski, Tomasz; Caglevic, Christian; Chung, Hyun C.; Muro, Kei; Van Cutsem, Eric; Elme, Anneli; Thuss-Patience, Peter; Chau, Ian; Ohtsu, Atsushi; Bhagia, Pooja; Wang, Anran; Shih, Chie-Schin; Shitara, Kohei
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061

KEYNOTE-061中使用二线pembrolizumab治疗晚期胃/胃食管交界癌的健康相关生活质量

GASTRIC CANCER
IF5.1
2021-08-0711
OAAI
Van Cutsem, Eric; Amonkar, Mayur; Fuchs, Charles S.; Alsina, Maria; Ozguroglu, Mustafa; Bang, Yung-Jue; Chung, Hyun Cheol; Muro, Kei; Goekkurt, Eray; Benson, Al B., III; Sun, Weijing; Wainberg, Zev A.; Norquist, Josephine M.; Chen, Xinqun; Shih, Chie-Schin; Shitara, Kohei
Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma
ANNALS OF ONCOLOGY
IF65.4
2021-07-0110
PREAI
Shitara, K.; Bang, Y.; Iwasa, S.; Sugimoto, N.; Ryu, M.; Sakai, D.; Chung, H.; Omuro, Y.; Kawakami, H.; Yabusaki, H.; Sakamoto, Y.; Nishina, T.; Inaki, K.; Kuwahara, Y.; Suto, F.; Sugihara, M.; Saito, K.; Kojima, A.; Yamaguchi, K.
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors

晚期肿瘤患者口服MDM2拮抗剂idasanutlin的每日和每周方案的I期研究

INVESTIGATIONAL NEW DRUGS
IF2.7
2021-06-2824
OAAI
Italiano, Antoine; Miller, Wilson H., Jr.; Blay, Jean-Yves; Gietema, Jourik A.; Bang, Yung-Jue; Mileshkin, Linda R.; Hirte, Hal W.; Higgins, Brian; Blotner, Steven; Nichols, Gwen L.; Chen, Lin Chi; Petry, Claire; Yang, Qi Joy; Schmitt, Christophe; Jamois, Candice; Siu, Lillian L.

研究方向

暂未获取到该数据
D
Do‐Youn Oh
H 指数:81论文数:950被引数:4.3万
S
Seock‐Ah Im
H 指数:98论文数:1,144被引数:6.9万
S
Sae‐Won Han
H 指数:57论文数:451被引数:1.1万
T
Tae‐You Kim
H 指数:55论文数:447被引数:1.7万
T
Tae‐You Kim
H 指数:46论文数:189被引数:2.0万
E
Eui Kyu Chie
H 指数:37论文数:380被引数:6,416
K
Kyung-Hun Lee
H 指数:45论文数:429被引数:1.0万
D
Dae Seog Heo
H 指数:77论文数:662被引数:2.3万
H
Hyun Cheol Chung
H 指数:86论文数:1,687被引数:5.5万
S
Sung Whan Ha
H 指数:31论文数:172被引数:2,689